No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
786 |
4. Check minimum number of eventsNone |
786 |
5. Include endpointsNone |
786 |
6. Filter based on genotype QC (FinnGen only) |
786 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF7
Similar endpoints
↥List of similar endpoints to
Graves ophthalmopathy, strict
based on the number of shared cases.
Similar with more cases:
- Graves ophthalmopathy
- Disorders of lacrimal system and orbit in diseases classified elsewhere
- Disorders of orbit
- Thyrotoxicosis, other and/or unspecified
- Thyrotoxicosis
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 3679 | 2975 | 690 |
| Only index persons | 3569 | 2906 | 663 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.09 | 0.02 |
| Only index persons | 0.09 | 0.11 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 51.38 | 51.28 | 51.88 |
| Only index persons | 51.22 | 51.20 | 51.31 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 786 | 643 | 143 |
| Unadjusted period prevalence (%) | 0.19 | 0.22 | 0.06 |
| Median age at first event (years) | 52.41 | 51.98 | 54.33 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 675
- Matched controls
- 6749
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
89.3
323.0
356
83
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
4503599627370496.0
323.0
668
*
H03BB01
ATC
carbimazole; oral
160.3
323.0
527
146
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
461.6
323.0
580
88
H03AA01
ATC
levothyroxine sodium; systemic
22.1
257.5
562
1240
BAA60
NOMESCO Finland
Total thyroidectomy
47.4
196.9
241
78
H06.2
ICD-10 Finland
Dysthyroid exophthalmos
2197.1
176.0
163
*
H062, E050
ICD-10 Finland
NA
499.3
162.9
156
*
104
Kela drug reimbursment
Thyroid insufficiency
14.1
140.7
265
296
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
36.3
129.5
168
61
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
7.9
125.0
530
2127
CA1BG
NOMESCO Finland
Eye and orbita MRI examination with high intensity magnet
163.8
106.7
110
8
E89.00
ICD-10 Finland
Postirradiation hypothyroidism
56.3
85.7
101
21
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.9
81.8
415
1650
H53.2
ICD-10 Finland
Diplopia
20.9
77.2
117
67
E05
ICD-10 Finland
Thyrotoxicosis [hyperthyroidism]
44.0
76.9
95
25
H05.2
ICD-10 Finland
Exophthalmic conditions
97.8
71.7
78
9
C07AA05
ATC
propranolol; systemic
4.9
69.2
287
880
H50.2
ICD-10 Finland
Vertical strabismus
81.4
65.6
73
10
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
42.2
58.0
72
19
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.4
49.6
166
381
XCK00
NOMESCO Finland
Perimetry
7.1
49.5
131
222
CAC30
NOMESCO Finland
Decompression of orbit to sinuses
+∞
48.5
46
*
H02AB06
ATC
prednisolone; systemic
3.2
45.5
430
2376
CAC44
NOMESCO Finland
Combined decompression of orbit
+∞
34.7
33
*
CEC00
NOMESCO Finland
Recession of extraocular muscle
68.8
34.4
39
6
CA1AD
NOMESCO Finland
Orbita CT
184.2
34.1
35
*
ZX120
NOMESCO Finland
Intravenous
4.5
34.0
132
344
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.5
31.9
100
206
ZXA10
NOMESCO Finland
Bilateral
3.2
31.5
197
761
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.4
31.4
181
659
BA1AE
NOMESCO Finland
Thyroiid ultrasound examination
12.9
30.3
54
45
H50.6
ICD-10 Finland
Mechanical strabismus
304.3
29.0
29
*
E06.2
ICD-10 Finland
Chronic thyroiditis with transient thyrotoxicosis
156.7
28.9
30
*
H50.8
ICD-10 Finland
Other specified strabismus
151.2
27.8
29
*
E05.2
ICD-10 Finland
Thyrotoxicosis with toxic multinodular goitre
14.4
27.2
46
34
H50.0
ICD-10 Finland
Convergent concomitant strabismus
29.1
26.9
36
13
A02BC02
ATC
pantoprazole; systemic
2.6
26.8
501
3563
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
26.8
195
825
XCD10
NOMESCO Finland
Electrophysiological examination of eye
9.7
26.7
55
61
WF099
NOMESCO Finland
Other radiotherapy
54.0
26.4
31
6
CAC20
NOMESCO Finland
Lateral decompression of orbit
+∞
26.2
25
*
CBK00
NOMESCO Finland
Myotomy or resection of tarsal muscle or levator muscle of eyelid for correction of retraction
+∞
25.2
24
*
H02AB07
ATC
prednisone; oral
3.1
24.4
151
567
H04.10
ICD-10 Finland
Dry eye syndrome
3.5
24.3
124
405
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
3.2
24.1
143
522
2AB04
NOMESCO Finland
NA
90.0
23.8
26
*
T86
ICPC
Hypothyroidism/myxoedema
5.6
21.7
65
126
E03.89
ICD-10 Finland
Other specified hypothyroidism
5.8
21.3
62
116
T85
ICPC
Hyperthyroidism/thyrotoxicosis
18.0
20.2
31
18
C07AB07
ATC
bisoprolol; oral
2.2
20.0
334
2111
L04AX03
ATC
methotrexate; systemic (immunosuppressants)
3.3
19.6
107
363
E05.1
ICD-10 Finland
Thyrotoxicosis with toxic single thyroid nodule
31.0
18.4
24
8
H02.5
ICD-10 Finland
Other disorders affecting eyelid function
45.3
18.3
22
5
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
5.2
18.3
58
120
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
6.3
18.2
49
83
E05.5
ICD-10 Finland
Thyroid crisis or storm
184.6
17.6
18
*
CEW99
NOMESCO Finland
Other operation on extraocular muscle
51.4
17.1
20
*
XCK10
NOMESCO Finland
Photography of fundus of eye
3.1
16.8
98
347
CEC90
NOMESCO Finland
Total transposition of extraocular muscle or muscles
+∞
16.7
16
*
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
18.5
16.6
25
14
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
5.8
16.2
46
84
CA1CM
NOMESCO Finland
Eye and orbita extensive MRI examination with 3 Tesla magnet
34.3
15.8
20
6
E03
ICD-10 Finland
Other hypothyroidism
3.5
15.5
76
238
YA1BD
NOMESCO Finland
Extensive CT examination of head and neck for dose design of radiotherapy
18.3
15.2
23
13
CEC60
NOMESCO Finland
Transposition of extraocular muscle with adjustable suture
46.1
15.1
18
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.9
14.6
298
1953
WX408
NOMESCO Finland
General anesthesy, balanced
2.1
14.6
217
1259
CA1BM
NOMESCO Finland
Eye and orbita MRI examination with 3 Tesla magnet
153.1
14.5
15
*
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
16.2
14.0
22
14
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
2.0
13.5
241
1492
E03.2
ICD-10 Finland
Hypothyroidism due to medicaments and other exogenous substances
18.7
13.4
20
11
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.0
13.3
80
289
XX7CT
NOMESCO Finland
Radioiodine therapy of thydoid tissue
10.8
12.8
24
23
N05CF01
ATC
zopiclone; oral
1.9
12.5
233
1457
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
3.4
12.3
60
188
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.4
12.2
61
194
O99.2
ICD-10 Finland
Endocrine, nutritional and metabolic diseases complicating pregnancy, childbirth and the puerperium
7.8
11.2
25
33
CE2W4
NOMESCO Finland
Eye movement mapping
44.1
10.9
13
*
YX8BD
NOMESCO Finland
Stereotactic extensive CT examination for dose design of radiotherapy
28.5
10.8
14
5
A11CC03
ATC
alfacalcidol; systemic
5.6
10.5
30
56
WX002
NOMESCO Finland
Sedation and analgesia
2.0
10.4
142
784
1XC02
NOMESCO Finland
NA
10.8
10.3
19
18
AAG50
NOMESCO Finland
Stereotactic intracranial radiotherapy
19.1
10.3
15
8
CS494
NOMESCO Finland
Other visual field testing
5.0
10.2
32
67
E89.09
ICD-10 Finland
Postprocedural hypothyroidism, other or several procedures
26.4
9.8
13
5
E89.0
ICD-10 Finland
Postprocedural hypothyroidism
55.8
9.7
11
*
C03EA01
ATC
hydrochlorothiazide and potassium-sparing agents; oral
2.0
9.0
119
647
CS424
NOMESCO Finland
Visual field testing with Goldmann perimetry
12.7
8.9
15
12
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
4.5
8.8
30
69
WF002
NOMESCO Finland
Radical radiotherapy
3.4
8.8
41
125
H03BA02
ATC
propylthiouracil; oral
50.6
8.7
10
*
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
4.8
8.2
26
56
WX402
NOMESCO Finland
General anaesthesia
1.9
8.1
123
699
106
Kela drug reimbursment
Hypoparathyroidism
11.9
8.1
14
12
TCC40
NOMESCO Finland
Closure of lacrimal canaliculus with plug
22.3
8.0
11
5
S01KA02
ATC
hypromellose; ophthalmic
5.0
8.0
24
49
E05.80
ICD-10 Finland
Subacute thyrotoxicosis
8.6
7.8
16
19
CD2S4
NOMESCO Finland
Photography of eye
18.6
7.6
11
6
ZX050
NOMESCO Finland
Stereotactic radiotherapy
12.0
7.6
13
11
CB9S4
NOMESCO Finland
Photography of eyelids and eyebrows
25.3
7.6
10
*
E05.89
ICD-10 Finland
Other thyrotoxicosis
10.2
7.6
14
14
A11CC02
ATC
dihydrotachysterol; oral
13.5
7.4
12
9
H57.1
ICD-10 Finland
Ocular pain
3.3
7.3
35
110
E83.51
ICD-10 Finland
Hypocalcemia
11.0
7.3
13
12
CS434
NOMESCO Finland
Visual field testing with Humphrey automated perimetry
4.6
6.8
22
49
H50.1
ICD-10 Finland
Divergent concomitant strabismus
9.4
6.8
13
14
H50.9
ICD-10 Finland
Strabismus, unspecified
40.4
6.8
8
*
2420A
ICD-9 Finland
Thyrotoxicosis with or without goitre, Toxic diffuse goitre
40.4
6.8
8
*
H01CB02
ATC
octreotide; parenteral
22.8
6.7
9
*
S01EE01
ATC
latanoprost; ophthalmic
2.8
6.6
40
149
YA1AD
NOMESCO Finland
CT examination of head and neck for dose design of radiotherapy
6.9
6.5
15
22
H50.52
ICD-10 Finland
Exophoria
6.9
6.5
15
22
ZXC95
NOMESCO Finland
Use of surgical navigator
5.8
6.5
17
30
ZXA00
NOMESCO Finland
Right side
1.6
6.5
174
1178
CBK99
NOMESCO Finland
Other operation for retraction of eyelid
70.5
6.4
7
*
CAB00
NOMESCO Finland
Anterior orbitotomy with excision of lesion
70.5
6.4
7
*
E03.0
ICD-10 Finland
Congenital hypothyroidism with diffuse goitre
7.5
6.4
14
19
J44.8
ICD-10 Finland
Other specified chronic obstructive pulmonary disease
2.4
6.4
49
209
H02AB09
ATC
hydrocortisone; systemic
3.9
6.3
24
63
WX140
NOMESCO Finland
Parabulbar anesthesy
3.2
6.3
31
101
H50.50
ICD-10 Finland
Alternating hyperphoria
+∞
6.3
6
*
E50.0
ICD-10 Finland
Vitamin A deficiency with conjunctival xerosis
+∞
6.3
6
*
G73.0*E05.9
ICD-10 Finland
Myasthenic syndromes in thyrotoxicosis [hyperthyroidism]
+∞
6.3
6
*
N07BA03
ATC
varenicline; oral
2.7
6.2
40
152
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.0
6.2
82
444
XX3DW
NOMESCO Finland
Time consuming IT work
2.0
6.2
75
391
S01GX01
ATC
cromoglicic acid; ophthalmic
1.7
6.2
153
1012
R00.0
ICD-10 Finland
Tachycardia, unspecified
3.0
6.0
32
110
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
423
207
43.08
307.65
5.2
1.7
6.0
5.2
iu/l
0.35
299
68
408
471
16.93
307.65
7.8
3.0
4.6
4.5
pmol/l
0.09
386
409
766
5502
16.41
59.67
14.9
4.3
15.9
14.6
pmol/l
32.23
740
5040
178
577
3.70
46.45
1.4
1.2
218.7
148.4
iu/ml
1.23
78
243
509
3209
2.66
37.25
7.3
6.1
1.2
1.2
mmol/l
1.74
431
2691
468
2910
2.50
34.04
6.3
5.3
1.2
1.2
mmol/l
1.41
439
2625
770
6367
11.28
31.90
16.4
5.0
1.6
2.1
mu/l
1.54
745
5856
138
504
3.11
28.84
2.9
3.5
52.8
81.0
ng/l
8.29
126
446
552
3874
2.43
28.20
9.2
8.8
3.9
4.0
e9/l
0.69
483
3405
369
2274
2.17
24.66
3.4
3.3
2.3
2.4
mmol/l
3.42
327
1997
430
2924
2.04
20.95
2.8
2.3
76.4
77.9
nmol/l
0.53
394
2629
637
5169
2.23
17.31
8.7
7.0
75.9
77.1
u/l
0.24
618
4841
134
651
2.28
15.23
2.4
2.1
360.9
374.3
nmol/l
0.38
123
600
32
69
4.79
14.11
3.8
4.5
49.9
58.8
u/ml
—
9
22
607
5041
1.90
12.58
4.6
4.1
11.6
11.7
mm/h
0.08
571
4649
478
3737
1.71
11.78
4.5
4.2
6.4
6.6
mmol/l
1.08
449
3484
365
2729
1.63
10.08
4.0
4.2
36.0
35.9
g/l
0.15
341
2546
749
6883
2.87
9.69
17.0
13.9
139.9
139.7
mmol/l
1.28
736
6699
349
2599
1.62
9.68
2.1
1.9
98.3
97.6
pmol/l
0.09
172
1281
750
6906
2.88
9.49
17.2
14.0
3.9
3.9
mmol/l
2.17
736
6709
235
1631
1.63
8.44
1.4
1.3
1.3
1.4
u/ml
0.07
54
444
730
6694
2.27
8.34
14.2
12.6
21.6
21.1
mg/l
0.14
577
5222
690
6207
1.91
8.23
6.1
5.4
38.9
39.3
mmol/mol
0.64
653
5772
716
6546
2.05
7.78
5.0
4.4
5.8
5.9
mmol/l
0.13
679
6009
179
1195
1.64
7.38
3.0
2.7
2.4
2.4
mmol/l
1.45
151
1054
236
1695
1.56
7.14
3.0
2.9
0.2
0.4
e6/l
1.35
170
1269
700
6401
1.86
6.86
14.1
11.4
83.9
82.8
ml/min/173m2
0.75
609
5238
42
174
2.49
6.80
1.2
1.3
55.5
42.4
u/ml
—
5
19
167
1135
1.60
6.32
4.3
3.4
245.2
295.0
ng/l
0.10
133
811
527
4536
1.49
6.31
3.4
2.9
36.1
44.6
u/l
2.85
504
4252
759
7182
2.65
6.25
14.1
9.9
24.0
24.8
u/l
0.95
746
6938
214
1543
1.53
6.24
2.1
2.1
—
—
—
0
0
141
924
1.64
6.18
2.9
2.7
4.6
3.3
e6/l
0.42
73
475
148
995
1.60
5.83
3.5
3.0
0.8
0.8
mmol/l
0.11
132
933
99
600
1.74
5.79
2.2
2.3
28.3
38.1
u/l
1.73
85
507
19
58
3.33
5.33
1.2
1.1
1.3
1.2
nmol/l
—
6
6
145
996
1.56
5.18
2.7
2.5
2.0
1.1
e6/l
0.60
77
543
109
728
1.58
4.38
2.1
2.4
5.8
6.7
umol/l
0.63
89
624
113
767
1.55
4.24
5.1
4.8
1.0
1.0
mmol/l
0.04
98
701
69
417
1.72
4.11
2.8
2.9
161.6
168.6
ng/l
0.06
61
387
15
48
3.17
3.94
1.9
1.8
—
—
—
0
0
274
2224
1.36
3.89
3.2
2.9
27.1
29.2
u/l
1.26
256
2121
44
243
1.86
3.56
1.6
2.2
—
—
—
0
0
661
6179
1.44
3.43
20.5
13.4
40.0
39.7
%
0.36
524
4542
39
210
1.90
3.41
1.7
1.6
—
166.7
—
0
9
148
1111
1.41
3.34
1.6
1.7
1055.7
1207.0
nmol/l
1.37
109
823
198
1560
1.36
3.34
2.6
2.1
2.6
3.0
mg/l
2.20
174
1320
37
199
1.90
3.26
1.6
1.6
0.3
0.1
iu/ml
—
6
32
352
3021
1.30
3.24
3.6
2.8
91.3
102.8
ug/l
0.69
324
2812
35
186
1.92
3.20
1.2
1.8
38.6
38.4
g/l
0.10
29
165
168
1310
1.36
3.00
2.5
2.5
7.1
7.1
e6/l
0.02
137
1153
36
199
1.85
2.94
1.2
2.0
1.0
0.5
g/l
0.19
30
180
16
66
2.45
2.72
1.2
1.2
—
—
—
0
0
37
213
1.77
2.68
1.2
1.8
9.5
10.3
g/l
0.87
30
187
391
3456
1.26
2.67
5.7
5.7
10.9
10.5
umol/l
0.50
372
3267
22
106
2.11
2.65
1.0
1.0
2.2
2.1
u/ml
—
6
46
161
1274
1.33
2.60
1.3
1.3
8.3
11.1
u/ml
0.22
50
504
37
216
1.75
2.56
1.2
1.8
3.0
3.1
g/l
0.33
30
175
21
101
2.11
2.55
1.2
1.1
3.1
1.6
u/ml
—
10
27
22
109
2.05
2.48
1.8
1.6
—
—
—
0
0
61
411
1.52
2.42
1.4
1.8
—
—
—
0
0
23
117
1.99
2.42
1.2
1.4
—
—
—
0
0
23
117
1.99
2.42
1.2
1.4
—
—
—
0
0
50
326
1.57
2.30
1.4
1.7
—
—
—
0
0
87
636
1.41
2.30
7.6
7.2
1.2
1.5
mmol/l
0.41
68
514
230
1937
1.26
2.30
2.2
2.1
163.9
196.1
u/l
0.27
209
1822
487
4460
1.24
2.27
3.1
3.1
—
—
—
0
0
220
1850
1.26
2.22
1.7
1.7
1.3
1.4
mmol/l
0.52
189
1565
54
365
1.51
2.14
1.0
1.0
—
—
—
0
0
37
229
1.65
2.12
1.2
1.8
7.5
7.6
g/l
0.05
30
183
37
229
1.65
2.12
1.2
1.8
—
—
—
0
0
37
229
1.65
2.12
1.2
1.8
4.3
3.8
g/l
0.30
29
173
57
392
1.49
2.09
1.3
1.3
30.4
30.8
iu/l
0.03
44
340
178
1470
1.27
2.08
1.4
1.5
19.5
21.6
nmol/l
1.48
155
1246
353
3151
1.22
2.01
3.5
3.8
—
—
—
0
0
162
1328
1.28
2.01
1.3
1.3
24.3
32.9
iu/ml
0.55
43
427
13
57
2.30
1.98
1.2
1.2
—
—
—
0
0
13
57
2.30
1.98
1.2
1.2
—
—
—
0
0
5
11
4.57
1.94
4.6
1.5
307.6
109.1
u/l
—
5
11
368
3308
1.21
1.93
5.0
4.8
0.0
0.0
estimate
0.50
67
624
20
106
1.91
1.92
1.3
1.1
2.7
5.8
u/ml
0.57
15
37
13
58
2.26
1.91
1.2
1.2
—
—
—
0
0
13
58
2.26
1.91
1.2
1.2
—
—
—
0
0
13
58
2.26
1.91
1.2
1.2
—
—
—
0
0
365
3282
1.21
1.90
3.5
3.6
0.0
0.0
estimate
0.00
66
623
370
3342
1.20
1.81
3.6
3.6
0.0
0.0
estimate
0.80
66
603
33
208
1.61
1.79
1.2
1.3
—
—
—
0
0
7
24
2.93
1.72
1.3
2.0
39.4
55.6
ug/l
—
7
24
37
244
1.54
1.68
1.5
1.8
—
—
—
0
0
224
1944
1.21
1.64
2.8
3.0
7.1
7.1
mmol/l
0.00
189
1627
696
6725
1.31
1.60
4.3
4.3
4.8
4.8
mmol/l
0.22
650
6256
8
32
2.52
1.60
1.0
1.1
—
—
—
0
0
19
106
1.81
1.60
1.6
1.6
—
—
—
0
0
85
662
1.32
1.57
1.8
1.8
—
—
—
0
0
118
960
1.27
1.56
1.9
1.8
—
—
—
0
0
65
486
1.37
1.56
1.4
2.7
65.8
67.3
g/l
0.82
56
447
107
860
1.28
1.56
2.6
2.2
2.4
2.4
g/l
0.22
98
794
8
33
2.44
1.54
1.0
1.0
—
—
—
0
0
10
44
2.29
1.53
1.1
1.1
—
—
—
0
0
71
541
1.34
1.52
3.4
3.5
1.2
1.2
mmol/l
1.39
66
461
66
499
1.35
1.49
2.6
2.9
0.7
0.8
ug/l
0.19
40
308
706
6847
1.31
1.47
5.0
4.8
2.9
2.9
mmol/l
0.44
655
6337
16
87
1.86
1.46
1.1
1.3
—
—
—
0
0
85
669
1.30
1.46
2.0
1.8
—
—
—
0
0
181
1558
1.21
1.44
2.1
1.7
0.9
1.0
mg/l
0.20
131
1196
26
166
1.59
1.39
1.5
3.5
33.8
42.3
mg/l
0.53
19
131
80
630
1.30
1.38
3.1
4.0
236.9
251.2
u/l
0.30
74
599
29
192
1.53
1.34
1.2
1.4
250.3
305.5
ug/g
0.78
16
114
5
18
2.79
1.28
1.0
1.2
—
—
—
0
0
152
1303
1.21
1.26
1.4
1.5
—
—
—
0
0
21
131
1.62
1.24
2.7
3.4
61.3
57.5
%
0.55
21
131
8
36
2.23
1.24
1.0
1.1
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
139
1.60
1.24
5.0
2.5
0.4
0.4
u/ml
—
7
72
23
147
1.58
1.24
1.3
1.2
18.2
13.4
u/l
0.55
18
118
36
256
1.43
1.20
2.7
2.9
24.9
24.3
mmol/l
0.63
36
232
8
38
2.12
1.18
1.1
1.1
—
—
—
0
0
20
125
1.62
1.18
2.6
3.0
5.0
4.2
e9/l
0.51
20
125
25
166
1.52
1.16
1.5
3.5
29.5
25.7
mg/l
0.40
18
129
33
233
1.43
1.15
1.1
1.3
208.9
237.2
miu/ml
0.16
17
110
12
65
1.86
1.14
1.8
1.6
—
—
—
0
0
85
694
1.25
1.13
17.6
20.9
1.4
1.2
inr
0.28
12
93
27
185
1.48
1.09
2.3
1.6
—
—
—
0
0
5
21
2.39
1.09
1.0
1.2
—
—
—
0
0
24
161
1.51
1.08
1.5
3.6
—
2.1
—
0
18
13
74
1.77
1.07
1.7
1.5
—
—
—
0
0
12
68
1.78
1.01
1.4
1.2
0.1
1.1
u/ml
—
7
24
687
6693
1.21
1.00
4.3
4.3
1.5
1.5
mmol/l
1.15
637
6195
112
955
1.20
1.00
2.8
2.2
13.6
13.3
umol/l
0.17
104
871
33
240
1.39
1.00
1.7
1.8
1.4
1.5
g/l
0.33
25
206
16
247
0.64
0.97
1.3
1.7
—
—
—
0
0
25
174
1.45
0.96
6.2
2.1
177.4
178.0
%
0.01
25
166
42
321
1.33
0.95
1.3
1.7
—
—
—
0
0
23
158
1.47
0.94
2.5
2.6
—
—
—
0
0
16
102
1.58
0.91
1.3
1.4
378.0
113.0
u/ml
—
5
26
21
144
1.47
0.88
1.9
1.6
1504.6
13102.1
e6/l
1.95
16
106
94
800
1.20
0.88
2.9
2.3
22.3
22.7
%
0.09
74
676
8
43
1.87
0.87
1.1
1.3
—
21.3
—
0
8
8
43
1.87
0.87
1.6
1.4
—
—
—
0
0
14
88
1.60
0.84
2.3
2.6
—
739.6
—
0
7
14
214
0.65
0.84
2.3
4.4
1.2
1.2
mmol/l
0.09
14
209
6
32
1.88
0.82
1.5
2.4
—
—
—
0
0
0
27
0.00
0.77
0.0
1.1
—
0.3
—
0
22
0
27
0.00
0.77
0.0
1.1
—
110.3
—
0
20
6
34
1.77
0.76
1.7
1.5
—
—
—
0
0
61
507
1.22
0.74
2.7
3.2
2.2
2.2
mmol/l
0.01
40
406
28
211
1.34
0.73
1.1
1.1
—
—
—
0
0
52
426
1.24
0.73
1.6
1.6
—
—
—
0
0
28
212
1.33
0.71
1.1
1.1
—
—
—
0
0
224
2079
1.11
0.64
2.7
2.3
52.4
55.9
u/l
0.99
209
1921
102
903
1.15
0.63
3.4
1.8
30.8
29.3
s
0.70
96
870
8
49
1.64
0.62
1.1
1.2
—
—
—
0
0
8
49
1.64
0.62
1.1
1.2
—
—
—
0
0
25
191
1.32
0.61
4.3
1.8
94.3
93.7
%
0.05
25
178
88
772
1.16
0.61
1.3
1.7
1.4
1.4
%
0.01
77
678
10
151
0.66
0.60
1.4
1.5
—
—
—
0
0
60
511
1.19
0.60
2.7
3.2
5.7
5.9
kpa
0.69
53
500
78
682
1.16
0.57
3.6
4.1
20.9
21.6
%
0.20
30
312
206
1914
1.10
0.57
3.8
3.9
6.8
6.6
mg/mmol
0.02
112
1142
659
6461
1.12
0.57
3.8
3.8
1.2
1.3
mmol/l
0.45
602
5946
44
525
0.83
0.56
2.2
2.4
65.8
68.5
ml/min/173m2
0.21
18
208
97
865
1.14
0.55
4.6
4.6
2.8
2.3
ug/l
0.31
86
762
8
126
0.63
0.54
1.3
1.7
—
—
—
0
0
54
630
0.85
0.54
1.7
1.7
—
—
—
0
0
15
108
1.40
0.53
1.1
1.1
—
—
—
0
0
10
66
1.52
0.52
2.1
3.5
—
—
—
0
0
6
40
1.50
0.51
1.0
1.2
—
—
—
0
0
14
187
0.74
0.46
2.3
4.3
3.9
3.8
mmol/l
0.25
14
176
24
193
1.25
0.44
1.4
1.5
—
—
—
0
0
73
816
0.88
0.43
7.4
6.6
—
—
—
0
0
5
32
1.57
0.42
1.2
1.7
—
—
—
0
0
5
33
1.52
0.41
1.0
1.4
—
—
—
0
0
0
17
0.00
0.40
0.0
3.0
—
—
—
0
0
0
17
0.00
0.40
0.0
3.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
7
104
0.67
0.39
1.7
1.5
—
—
—
0
0
66
590
1.13
0.39
2.3
2.1
0.2
0.2
g/l
0.02
59
553
12
89
1.35
0.38
2.3
1.7
—
—
—
0
0
5
37
1.35
0.37
2.2
2.2
—
—
—
0
0
22
182
1.21
0.33
1.2
1.2
—
—
—
0
0
44
388
1.14
0.33
1.2
1.4
—
—
—
0
0
6
90
0.66
0.33
1.7
1.6
—
—
—
0
0
13
101
1.29
0.32
1.1
1.1
—
—
—
0
0
248
2380
1.06
0.31
2.9
3.3
24.8
46.9
ng/l
0.68
129
1521
28
239
1.18
0.31
1.6
1.9
—
—
—
0
0
169
1781
0.93
0.31
3.9
4.0
0.0
0.0
estimate
0.80
68
621
176
1673
1.07
0.30
2.4
2.8
1110.7
865.7
ng/l
0.37
147
1392
14
111
1.27
0.30
1.2
1.2
—
—
—
0
0
11
140
0.78
0.28
1.1
1.7
—
—
—
0
0
9
117
0.77
0.27
2.3
1.6
—
—
—
0
0
26
225
1.16
0.26
1.4
1.7
—
—
—
0
0
160
1525
1.06
0.26
1.4
1.4
—
—
—
0
0
5
71
0.70
0.26
3.0
1.8
—
—
—
0
0
25
216
1.16
0.25
1.4
1.5
—
—
—
0
0
137
1442
0.94
0.25
3.6
4.0
1.0
1.0
kg/l
0.57
18
185
51
464
1.11
0.25
8.4
6.7
8.6
8.6
mmol/l
0.03
45
444
171
1636
1.06
0.25
2.4
2.4
7695.0
5317.5
umol/l
0.23
153
1406
11
87
1.27
0.24
1.0
1.1
—
—
—
0
0
6
85
0.70
0.24
1.3
1.9
6.8
52.0
u/ml
—
6
79
16
134
1.20
0.23
2.1
2.1
131.6
130.2
g/l
0.08
11
98
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
40
1.25
0.22
1.0
1.2
—
—
—
0
0
18
210
0.85
0.22
1.2
1.4
81.8
237.1
pmol/l
1.19
18
205
5
41
1.22
0.22
1.2
1.2
—
—
—
0
0
59
636
0.92
0.21
2.9
4.2
11.8
15.2
ug/l
0.16
46
514
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
250
2574
0.96
0.21
3.8
3.7
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
11
134
0.82
0.20
4.5
3.8
37.6
23.7
mg/l
—
5
79
21
183
1.15
0.20
1.3
1.4
—
—
—
0
0
21
183
1.15
0.20
1.3
1.4
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
6
51
1.18
0.19
1.0
1.2
—
—
—
0
0
6
51
1.18
0.19
3.2
1.6
—
—
—
0
0
21
184
1.15
0.19
1.3
1.4
—
—
—
0
0
21
184
1.15
0.19
1.3
1.4
—
—
—
0
0
7
58
1.21
0.18
3.1
2.0
—
—
—
0
0
7
61
1.15
0.17
1.1
1.1
—
61.9
—
0
8
7
61
1.15
0.17
1.1
1.1
—
43.2
—
0
5
21
187
1.13
0.16
1.1
1.1
—
—
—
0
0
10
83
1.21
0.15
1.0
1.3
—
—
—
0
0
40
371
1.08
0.15
1.4
1.5
—
—
—
0
0
9
81
1.11
0.15
1.2
1.1
—
—
—
0
0
7
89
0.78
0.14
2.7
1.6
—
—
—
0
0
8
98
0.81
0.13
2.8
1.7
53.5
43.3
nmol/l
—
8
93
63
663
0.95
0.13
3.2
3.0
—
—
—
0
0
34
315
1.08
0.13
1.3
1.5
—
—
—
0
0
9
107
0.84
0.13
1.0
1.5
—
—
—
0
0
28
258
1.09
0.12
1.5
2.0
217.6
3958.9
u/l
—
9
104
19
171
1.11
0.12
2.3
3.7
16.5
33.9
u/ml
1.51
19
166
5
44
1.14
0.10
1.6
1.3
—
—
—
0
0
10
114
0.88
0.09
2.4
1.7
—
—
—
0
0
85
825
1.03
0.08
4.6
4.4
32.6
33.0
%
0.13
58
543
5
61
0.82
0.08
1.8
1.5
—
—
—
0
0
5
61
0.82
0.08
1.8
1.5
—
—
—
0
0
5
61
0.82
0.08
1.8
1.5
—
—
—
0
0
74
764
0.97
0.08
1.9
1.9
—
—
—
0
0
7
67
1.05
0.08
1.3
1.1
—
—
—
0
0
7
82
0.85
0.07
1.0
1.1
—
—
—
0
0
17
157
1.08
0.07
1.4
1.5
11.3
6.4
e6/l
—
10
123
17
157
1.08
0.07
1.4
1.5
681.3
145.1
e6/l
0.37
11
127
14
128
1.10
0.06
1.0
1.1
0.4
2.5
u/ml
—
8
44
46
477
0.96
0.06
2.2
2.4
7.1
5.7
ug/l
0.27
37
423
20
189
1.06
0.04
1.5
1.3
—
—
—
0
0
10
92
1.09
0.03
1.1
1.2
14.1
22.9
u/l
—
10
79
16
152
1.05
0.02
2.1
1.7
—
—
—
0
0
136
1370
0.99
0.01
1.6
1.7
105172841.8
22397640.8
pmol/l
0.57
116
1143
14
147
0.95
0.01
1.1
1.4
—
—
—
0
0
12
126
0.95
0.00
3.8
3.8
200.3
2317.2
u/ml
0.56
12
118
35
344
1.02
0.00
3.0
3.2
1.7
1.9
mmol/l
0.14
29
259
68
686
0.99
0.00
1.7
1.8
—
—
—
0
0
11
105
1.05
0.00
1.2
1.2
356.7
264.7
u/ml
—
6
65
17
165
1.03
0.00
1.3
1.3
—
—
—
0
0
11
114
0.96
0.00
1.2
1.2
—
—
—
0
0
11
114
0.96
0.00
2.4
1.7
—
—
—
0
0
14
137
1.02
0.00
2.1
2.4
5.3
93.2
ug/min
—
9
79
28
284
0.99
0.00
1.7
1.8
2.5
4.8
mg/l
0.58
18
201
33
334
0.99
0.00
1.7
1.5
—
—
—
0
0
15
152
0.99
0.00
1.1
1.2
—
—
—
0
0
16
159
1.01
0.00
2.1
1.7
—
—
—
0
0
17
171
0.99
0.00
1.6
1.7
—
—
—
0
0
34
339
1.00
0.00
1.3
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
0.00
0.0
10.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
6.5
—
0
8
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
12
120
1.00
0.00
2.2
1.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
8
83
0.96
0.00
1.0
1.5
—
—
—
0
0
8
83
0.96
0.00
1.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
8
84
0.95
0.00
1.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
1.3
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
8
84
0.95
0.00
1.0
1.5
—
—
—
0
0
8
85
0.94
0.00
1.0
1.5
—
—
—
0
0
9
96
0.94
0.00
1.0
1.2
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
8
85
0.94
0.00
1.0
1.5
—
—
—
0
0
5
59
0.85
0.00
1.4
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_GRAVES_OPHT_STRICT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_GRAVES_OPHT_STRICT | 1.019 [0.88, 1.18] | 0.809 |
| Birth year | 0.997 [0.99, 1.01] | 0.467 |
During the follow-up period (1.1.1998 — 31.12.2019), 232 out of 2730 females with E4_GRAVES_OPHT_STRICT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_GRAVES_OPHT_STRICT | 0.955 [0.75, 1.22] | 0.706 |
| Birth year | 0.988 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 86 out of 636 males with E4_GRAVES_OPHT_STRICT died.
Mortality risk
Mortality risk for people of age
years, who have E4_GRAVES_OPHT_STRICT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.132% | 0.18% |
| 5 | 0.714% | 1.192% |
| 10 | 1.575% | 3.121% |
| 15 | 2.786% | 5.749% |
| 20 | 5.019% | 9.82% |
Relationships between endpoints
↥Index endpoint: E4_GRAVES_OPHT_STRICT – Graves ophthalmopathy, strict
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data